Browse > Article
http://dx.doi.org/10.5010/JPB.2010.37.3.283

Development of adjuvant for effective oral vaccine application  

Kim, Sae-Hae (Division of Biological Sciences, Chonbuk National University)
Seo, Ki-Weon (Division of Biological Sciences, Chonbuk National University)
Kim, Ju (Jeonju Biomaterials Institute)
Jang, Yong-Suk (Division of Biological Sciences, Chonbuk National University)
Publication Information
Journal of Plant Biotechnology / v.37, no.3, 2010 , pp. 283-291 More about this Journal
Abstract
Vaccine is one of the best known and most successful applications of immunological theory to human health and it protects human life through inducing the immune response in systemic compartment. However, when we consider the fact that mucosal epithelium is exposed to diverse foreign materials including viruses, bacteria, and food antigens and protects body from entry of unwanted materials using layer of tightly joined epithelial cells, establishing the immunological barrier on the lining of mucosal surfaces is believed to be an effective strategy to protect body from unwanted antigens. Unfortunately, however, oral mucosal site, which is considered as the best target to induce mucosal immune response due to application convenience, is prone to induce immune tolerance rather than immune stimulation. Since intestinal epithelium is tightly organized, a prerequisite for successful mucosal vaccination is delivery of antigen to mucosal immune induction site including a complex system of highly specialized cells such as M cells. Consequently, development of efficient mucosal adjuvant capable of introducing antigens to mucosal immune induction site and overcome oral tolerance is an important subject in oral vaccine development. In this review, various approaches on the development of oral mucosal adjuvants being suggested for effective oral mucosal immune induction.
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Duc M, Johansen FE, Corthesy B. (2010) Antigen binding to secretory immunoglobulin A results in decreased sensitivity to intestinal proteases and increased binding to cellular Fc receptors. J Biol Chem 285:953-960   DOI
2 Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K (2010) Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol 28:243-273   DOI
3 Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V, Vanderhaeghen ML, Jerome C, Vanderplasschen A, Marchand-Brynaert J, Schneider YJ, Preat V (2009) Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 73:16-24   DOI
4 Gebert A, Rothkotter HJ, Pabst R (1996) M cells in Peyer’s patches of the intestine. Int Rev Cytol 167:91-159   DOI
5 Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H (2009) Uptake through glycoprotein 2 of FimH (+) bacteria by M cells initiates mucosal immune response. Nature 462:226-230   DOI
6 Abreu MT (2010) Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 10:131-144   DOI
7 Bevan MJ (2004) Helping the CD8 (+) T-cell response. Nat Rev Immunol 4:595-602   DOI
8 Takahashi I, Nochi T, Yuki Y, Kiyono H (2009) New horizon of mucosal immunity and vaccines. Curr Opin Immunol 21:352-258   DOI
9 Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, Kurokawa S, Takahashi Y, Nanno M, Nakanishi U, Takaiwa F, Honda T, Kiyono H (2010) Secretory IgA- mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci USA 107:8794-8799   DOI
10 Tomasi Jr TB, Tan EM, Solomon A, Prendergast RA (1965) Characteristics of an immune system common to certain external secretions. J Exp Med 121:101-124   DOI
11 Brandtzaeg P, Kiyono H, Pabst R, Russell MW (2008) Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 1:31-37   DOI   ScienceOn
12 Blanco HM, Lacoste MG, Elicabe RJ, Di Genaro MS (2008) IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: implications for its use as oral carrier vaccine. Vaccine 26:6497-6502   DOI
13 Brandtzaeg P (2009) Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 70:505-515   DOI   ScienceOn
14 Brandtzaeg P, Johansen FE (2005) Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206:32-63   DOI
15 Brayden DJ, Jepson MA, Baird AW (2005) Keynote review: intestinal Peyer’s patch M cells and oral vaccine targeting. Drug Discov Today 10:1145-1157   DOI
16 Cerutti A (2008) The regulation of IgA class switching. Nat Rev Immunol 8:421-434   DOI
17 Cerutti A, Rescigno M (2008) The biology of intestinal immunoglobulin A responses. Immunity 28:740-750   DOI
18 Chadwick S, Kriegel C, Amiji M (2010) Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 62:394-407   DOI
19 Tyrer PC, Ruth Foxwell A, Kyd JM, Otczyk DC, Cripps AW (2007) Receptor mediated targeting of M-cells. Vaccine 25:3204-3209   DOI
20 Tsuji NM, Kosaka A (2008) Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 29:532-540   DOI   ScienceOn
21 Wershil BK, Furuta GT (2008) 4. Gastrointestinal mucosal immunity. J Allergy Clin Immunol 121:S380-383   DOI
22 Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW (2001) M cell-targeted DNA vaccination. Proc Natl Acad Sci USA 98:9318-9323   DOI
23 Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, Fukuyama S, Iwatsuki-Horimoto K, Kawaoka Y, Kohda T, Kozaki S, Igarashi O, Kiyono H (2007) A novel M cellspecific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 204:2789-2796   DOI   ScienceOn
24 Parrott DM (1976) The gut as a lymphoid organ. Clin Gastroenterol 5:211-228   DOI
25 Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11:S5-11
26 Siebers A, Finlay BB (1996) M cells and the pathogenesis of mucosal and systemic infections. Trends Microbiol 4:22-29   DOI
27 Ragnarsson EG, Schoultz I, Gullberg E, Carlsson AH, Tafazoli F, Lerm M, Magnusson KE, Soderholm JD, Artursson P (2008) Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasindependent macropinocytosis. Lab Invest 88:1215-1226   DOI
28 Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23-32   DOI
29 Rynda A, Maddaloni M, Mierzejewska D, Ochoa-Reparaz J, Maslanka T, Crist K, Riccardi C, Barszczewska B, Fujihashi K, McGhee JR, Pascual DW (2008) Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma 1. J Immunol 180:5187-5200   DOI
30 Slutter B, Plapied L, Fievez V, Sande MA, des Rieux A, Schneider YJ, Van Riet E, Jiskoot W, Preat V (2009) Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 138:113-121   DOI
31 Sun JB, Czerkinsky C, Holmgren J (2010) Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 71:1-11   DOI
32 Man AL, Lodi F, Bertelli E, Regoli M, Pin C, Mulholland F, Satoskar AR, Taussig MJ, Nicoletti C (2008) Macrophage migration inhibitory factor plays a role in the regulation of microfold (M) cell-mediated transport in the gut. J Immunol 181:5673-5680   DOI
33 Marra A, Isberg RR (1997) Invasin-dependent and invasinindependent pathways for translocation of Yersinia pseudotuberculosis across the Peyer’s patch intestinal epithelium. Infect Immun 65:3412-3421
34 Misumi S, Masuyama M, Takamune N, Nakayama D, Mitsumata R, Matsumoto H, Urata N, Takahashi Y, Muneoka A, Sukamoto T, Fukuzaki K, Shoji S (2009) Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J Immunol 182:6061-6070   DOI
35 McGhee JR, Kunisawa J, Kiyono H (2007) Gut lymphocyte migration: we are halfway ‘home’. Trends Immunol 28:150-153   DOI
36 Mestecky J, Nguyen H, Czerkinsky C, Kiyono H (2008) Oral immunization: an update. Curr Opin Gastroenterol 24:713-719   DOI   ScienceOn
37 Mishra N, Goyal AK, Tiwari S, Paliwal R, Paliwal SR, Vaidya B, Mangal S, Gupta M, Dube D, Mehta A, Vyas SP (2010) Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat 20:661-679   DOI
38 Nochi T, Yuki Y, Katakai Y, Shibata H, Tokuhara D, Mejima M, Kurokawa S, Takahashi Y, Nakanishi U, Ono F, Mimuro H, Sasakawa C, Takaiwa F, Terao K, Kiyono H (2009) A rice-based oral cholera vaccine induces macaque- specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. J Immunol 183:6538-6544   DOI
39 Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45-53   DOI
40 Iwasaki A (2007) Mucosal dendritic cells. Annu Rev Immunol 25:381-418   DOI
41 Jepson MA, Clark MA, Hirst BH (2004) M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev 56:511-525   DOI
42 Keljo DJ, Hamilton JR (1983) Quantitative determination of macromolecular transport rate across intestinal Peyer’s patches. Am J Physiol 244:G637-644
43 Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, Tsuji M, Palese P (2009) Alpha-Cgalactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27:3766-3774   DOI
44 Kendall MA (2010) Needle-free vaccine injection. Handb Exp Pharmacol 193-219
45 Kiyono H, Fukuyama S (2004) NALT- versus Peyer’s-patchmediated mucosal immunity. Nat Rev Immunol 4:699-710   DOI
46 Knoop KA, Kumar N, Butler BR, Sakthivel SK, Taylor RT, Nochi T, Akiba H, Yagita H, Kiyono H, Williams IR (2009) RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol 183:5738-5747   DOI
47 Kuolee R, Chen W (2008) M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv 5:693-702   DOI   ScienceOn
48 Mach J, Hshieh T, Hsieh D, Grubbs N, Chervonsky A (2005) Development of intestinal M cells. Immunol Rev 206:177-189   DOI   ScienceOn
49 Chen D, Endres RL, Erickson CA, Maa YF, Payne LG (2002) Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine 20:2671-2679   DOI
50 Chwalek M, Lalun N, Bobichon H, Ple K, Voutquenne-Nazabadioko L (2006) Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction. Biochim Biophys Acta 1760:1418-1427   DOI   ScienceOn
51 Clark MA, Jepson MA (2003) Intestinal M cells and their role in bacterial infection. Int J Med Microbiol 293:17-39   DOI